(Q92857414)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

title

The application of metabolomics toward pulmonary tuberculosis research (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

pulmonary tuberculosis

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Ilse du Preez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Laneke Luies

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

publication date

9 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

126-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier

2 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of Mycobacterium tuberculosis on fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics biomarkers for tuberculosis diagnostics: current status and future objectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The role of metabolomics in tuberculosis treatment research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The Metabolomic Strategy in Tuberculosis Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Clinical metabolomics paves the way towards future healthcare strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

HMDB: the Human Metabolome Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

7 January 2021

Metabolomics: A Primer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Deregulated tyrosine-phenylalanine metabolism in pulmonary tuberculosis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a 1H NMR based metabolomics approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A metabolic biosignature of early response to anti-tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A metabolomics approach to characterise and identify various Mycobacterium species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the rpoB Gene of Mycobacterium tuberculosis: mapping the potential of pharmaco-metabolomics for global health and personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Rifampin Resistance Mutations Are Associated with Broad Chemical Remodeling of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Effects of pre-analytical processes on blood samples used in metabolomics studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Analytical pitfalls and challenges in clinical metabolomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Sample normalization methods in quantitative metabolomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics for laboratory diagnostics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Analytical methods in untargeted metabolomics: state of the art in 2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Chemometric methods in data processing of mass spectrometry-based metabolomics: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Statistical methods for the analysis of high-throughput metabolomics data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Chemometrics in metabolomics--a review in human disease diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Navigating freely-available software tools for metabolomics analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Effects of colistin on surface ultrastructure and nanomechanics of Pseudomonas aeruginosa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Lipidomic analyses of Mycobacterium tuberculosis based on accurate mass measurements and the novel "Mtb LipidDB"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics of Mycobacterium tuberculosis Reveals Compartmentalized Co-Catabolism of Carbon Substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A metabolomics approach exploring the function of the ESX-3 type VII secretion system of M. smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Comparative metabolic profiling of mce1 operon mutant vs wild-type Mycobacterium tuberculosis strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Multisystem Analysis of Mycobacterium tuberculosis Reveals Kinase-Dependent Remodeling of the Pathogen-Environment Interface.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The Mycobacterium tuberculosis regulatory network and hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Cell-Envelope Remodeling as a Determinant of Phenotypic Antibacterial Tolerance in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Glutamate mediated metabolic neutralization mitigates propionate toxicity in intracellular Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A comparison of four sputum pre-extraction preparation methods for identifying and characterising Mycobacterium tuberculosis using GCxGC-TOFMS metabolomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A fast method for the identification of Mycobacterium tuberculosis in sputum and cultures based on thermally assisted hydrolysis and methylation followed by gas chromatography-mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Validation of biomarkers for distinguishing Mycobacterium tuberculosis from non-tuberculous mycobacteria using gas chromatography-mass spectrometry and chemometrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Direct detection of Mycobacterium tuberculosis in sputum using combined solid phase extraction-gas chromatography-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Direct detection of Mycobacterium tuberculosis in sputum: A validation study using solid phase extraction-gas chromatography-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Procedures for collection of induced sputum specimens from children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Correction: Biomarkers of Inflammation, Immunosuppression and Stress with Active Disease Are Revealed by Metabolomic Profiling of Tuberculosis Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolite changes in blood predict the onset of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The application of metabonomics to predict drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Derivatization of carbohydrates for GC and GC-MS analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Recent and potential developments in the analysis of urine: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Predicting tuberculosis treatment outcome using metabolomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Urinary metabolite markers characterizing tuberculosis treatment failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomic signatures in guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

(1)H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The association between sterilizing activity and drug distribution into tuberculosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Volatile biomarkers of pulmonary tuberculosis in the breath.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The scent of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

The scent of Mycobacterium tuberculosis--part II breath.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Application of 'omics technologies to biomarker discovery in inflammatory lung diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Confronting the scientific obstacles to global control of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Identification of Mycobacterium tuberculosis using volatile biomarkers in culture and exhaled breath

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Lipidomics and genomics of Mycobacterium tuberculosis reveal lineage-specific trends in mycolic acid biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Identification of specific metabolites in culture supernatant of Mycobacterium tuberculosis using metabolomics: exploration of potential biomarkers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Predicting the in vivo mechanism of action for drug leads using NMR metabolomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Imidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Mutations of Mycobacterium tuberculosis induced by anti-tuberculosis treatment result in metabolism changes and elevation of ethambutol resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A metabolomics investigation of the function of the ESX-1 gene cluster in mycobacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolic anticipation in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Rapid method for Mycobacterium tuberculosis identification using electrospray ionization tandem mass spectrometry analysis of mycolic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Hyphenated and comprehensive liquid chromatography × gas chromatography-mass spectrometry for the identification of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Analysis of serum metabolic profile by ultra-performance liquid chromatography-mass spectrometry for biomarkers discovery: application in a pilot study to discriminate patients with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

High-resolution plasma metabolomics analysis to detect Mycobacterium tuberculosis-associated metabolites that distinguish active pulmonary tuberculosis in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Use of Urine Volatile Organic Compounds To Discriminate Tuberculosis Patients from Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Development of colorimetric sensor array for diagnosis of tuberculosis through detection of urinary volatile organic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Melatonin prevents the free radical and MADD metabolic profiles induced by antituberculosis drugs in an animal model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Metabolomics of urine for the assessment of microvesicular lipid accumulation in the liver following isoniazid exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Pharmacometabonomic Characterization of Xenobiotic and Endogenous Metabolic Phenotypes That Account for Inter-individual Variation in Isoniazid-Induced Toxicological Response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Breath biomarkers of active pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Point-of-care breath test for biomarkers of active pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Breath analysis as a potential diagnostic tool for tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Diagnosis of active tuberculosis by e-nose analysis of exhaled air.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

Identification of Mycobacterium tuberculosis and M. avium complex directly from smear-positive sputum specimens and BACTEC 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition mod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.03.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2019.03.003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948167%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference